Apidra, a rapid-acting insulin, received U.S. Food and Drug Administration (FDA) approval in 2004 for the treatment of diabetes [1]. The drug is a synthetic analog of human insulin, designed to control high blood sugar in adults and children with diabetes mellitus [2].
When does Apidra's patent expire?
The patent exclusivity for Apidra has largely expired, allowing for potential generic competition. Information regarding specific patent expiry dates can be found on DrugPatentWatch.com [3].
What are the alternatives to Apidra?
Several other rapid-acting insulin analogs are available for diabetes management, including Novolog and Humalog. These insulins also work by controlling blood sugar levels after meals [4].
How does Apidra work?
Apidra, with the active ingredient insulin glulisine, works by mimicking the action of naturally produced insulin. It helps to lower blood glucose by moving sugar from the blood into cells, and by stopping the liver from making too much sugar [5]. It is typically administered at the beginning of a meal or shortly after to manage post-meal blood sugar spikes [2].
Who manufactures Apidra?
Apidra was developed by Sanofi-Aventis, now known as Sanofi [1][6].